Zentiva rejects Sanofi-Aventis's offer
This article was originally published in Scrip
Zentiva's board says the acquisition offer made by Sanofi-AventisEurope, a wholly owned subsidiary of Sanofi-Aventis, earlier this month underestimated its value and future prospects. The board recommended Zentiva's shareholders to reject the offer under which its shares were valued at CK1,050 ($71.40) each (Scrip Online, July 15th, 2008).
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.